TAXOL AND SDZ PSC 833 IN PATIENTS WITH REFRACTORY MALIGNANCIES

紫杉醇和 SDZ PSC 833 在难治性恶性肿瘤患者中的应用

• 批准号: 6274210
• 负责人: PAULA M. FRACASSO
• 金额: $ 2.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274210
• 关键词: antineoplastics; clinical research; clinical trial phase I; combination chemotherapy; cyclosporines; drug screening /evaluation; human subject; human therapy evaluation; multidrug resistance; neoplasm /cancer; neoplasm /cancer chemotherapy; paclitaxel

This study is to define the maximum tolerated dose of paclitaxel and SDZ PSC 833 in patients with refractory solid tumor malignancies. After defining the maximum tolerated doses of these drugs in combination, it is envisioned that future studies will examine whether the addition of SDZ PSC 833, a cyclosporine analog which has been found in vitro and in vivo to reverse multidrug resistance, will reverse resistance in solid tumor malignancies.

本研究旨在确定紫杉醇和SDZ的最大耐受剂量